Design, synthesis and activity evaluation of reduction-responsive anticancer peptide temporin-1CEa drug conjugates
Bioorganic Chemistry · 2025
DOI: 10.1016/j.bioorg.2024.108103 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2025. Verfasst von Zhenbin Han und 5 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical Unive…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Drug Design, Drug Screening Assays, Antitumor. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Program for Liaoning Innovative Talents in University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Membranes that destroy anticancer peptides can bind to negatively charged cancer cell membranes through electrostatic interactions, destroying their functions and leading to cancer cell necrosis. Temporin-1CEa, obtained from the skin secretions of the Chinese frog Rana chensinensis, is an anticancer peptide with 17 amino acid residues that exhibits concentration-dependent cytotoxicity against a variety of cancer cell lines, although it has no obvious cytotoxicity to normal HUVECs. In this work, we designed and synthesized 12 derivative peptides through double-cysteine scanning of temporin-1CEa-truncated peptides. Most of these peptides had greater anticancer activity than the lead peptide temporin-1CEa. Among these derivative peptides, Nu-7 had the strongest anticancer activity. Nu-7 has a greater α-helicity than does temporin-1CEa. We connected Nu-7 to podophyllotoxin through a reduction-responsive linker to obtain Nu-7-1, which showed better anticancer activity than free podophyllotoxin. Nu-7-1 was less toxic to HUVECs and had low hemolytic activity at therapeutic concentrations (although Nu-7-1 showed hemolytic activity at 100 μM). Nu-7-1 functions through two mechanisms: damage to cell membranes and promotion of cell apoptosis. Nu-7-1 is less toxic to normal HUVECs than is podophyllotoxin and shows better safety. In summary, we carried out a series of modifications on temporin-1CEa, among which the anticancer activity of Nu-7-1 was significantly improved compared with that of the lead peptide temporin-1CEa, providing a useful reference for the structural modification of anticancer peptides.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China.
- Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China. Electronic address: yanghl@syphu.edu.cn.
- Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China. Electronic address: y.liu@syphu.edu.cn.
Förderung
- Program for Liaoning Innovative Talents in University
- National Natural Science Foundation of China
Zitieren
APA
Han, Z., Wang, Y., Wang, W., Cheng, M., Yang, H., & Liu, Y. (2025). Design, synthesis and activity evaluation of reduction-responsive anticancer peptide temporin-1CEa drug conjugates. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2024.108103
Vancouver
Han Z, Wang Y, Wang W, Cheng M, Yang H, Liu Y. Design, synthesis and activity evaluation of reduction-responsive anticancer peptide temporin-1CEa drug conjugates. Bioorganic Chemistry. 2025. doi:10.1016/j.bioorg.2024.108103
BibTeX
@article{Han2025,
author = {Han, Zhenbin and Wang, Yue and Wang, Wenxuan and Cheng, Maosheng and Yang, Huali and Liu, Yang},
title = {Design, synthesis and activity evaluation of reduction-responsive anticancer peptide temporin-1CEa drug conjugates},
journal = {Bioorganic Chemistry},
year = {2025},
doi = {10.1016/j.bioorg.2024.108103}
}
EUVIMED